Paul B. Manning
CIK: 0001494695
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (33 total)
- Sep 30, 2026CADL
Candel Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
2.2K shares at avg. $8.68- - Jun 30, 2026CADL
Candel Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
2.2K shares at avg. $8.64- - Jun 23, 2026CADL
Candel Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
32K shares- - Jun 16, 2026LQDA
Liquidia Corp
Award(A)Direct5.9K shares- - Jun 4, 2026LQDA
Liquidia Corp
Sale(S)Indirect11.5K shares at avg. $63.13$727K - Jun 4, 2026LQDA
Liquidia Corp
Sale(S)Indirect88.5K shares at avg. $64.28$5.7M - Jun 4, 2026LQDA
Liquidia Corp
Sale(S)Indirect19.1K shares at avg. $62.62$1.2M - Jun 4, 2026LQDA
Liquidia Corp
Sale(S)Indirect68.3K shares at avg. $63.83$4.4M - Jun 4, 2026LQDA
Liquidia Corp
Sale(S)Indirect12.6K shares at avg. $64.42$812K - Mar 31, 2026CADL
Candel Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
4.6K shares at avg. $4.11- - Feb 23, 2026CADL
Candel Therapeutics, Inc.
Purchase(P)Indirect550.5K shares at avg. $5.45$3.0M - Feb 11, 2026LQDA
Liquidia Corp
Other(J)Indirect55.1K shares at avg. $42.63$2.3M - Feb 11, 2026LQDA
Liquidia Corp
Other(J)Direct55.1K shares at avg. $42.63$2.3M - Nov 25, 2025VRCA
Verrica Pharmaceuticals Inc.
Purchase(P)Indirect2.8M shares at avg. $4.24$11.7M - Nov 25, 2025VRCA
Verrica Pharmaceuticals Inc.
Purchase(P)Direct1.4M shares at avg. $4.24$5.8M - Sep 2, 2025LQDA
Liquidia Corp
Sale(S)Indirect74.2K shares at avg. $29.14$2.2M - Sep 2, 2025LQDA
Liquidia Corp
Sale(S)Indirect254K shares at avg. $28.67$7.3M - Aug 29, 2025LQDA
Liquidia Corp
Sale(S)Indirect188.2K shares at avg. $27.62$5.2M - Aug 28, 2025LQDA
Liquidia Corp
Sale(S)Indirect154.3K shares at avg. $27.94$4.3M - Jun 25, 2025CADL
Candel Therapeutics, Inc.
Award(A)Indirect1.1M shares at avg. $4.67$5.0M - Jun 17, 2025LQDA
Liquidia Corp
Award(A)Direct18.4K shares- - Jun 17, 2025CADL
Candel Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
14.2K shares- - May 30, 2025TSHA
Taysha Gene Therapies, Inc.
Purchase(P)Indirect750K shares at avg. $2.75$2.1M - Dec 16, 2024CADL
Candel Therapeutics, Inc.
Purchase(P)Indirect500K shares at avg. $6.00$3.0M - Dec 16, 2024CADL
Candel Therapeutics, Inc.
Purchase(P)Indirect750K shares at avg. $6.00$4.5M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 30, 2026 |  CADL Candel Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 2,189 | $8.68 | - | Direct |
| Jun 30, 2026 | CADL Candel Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 2,199 | $8.64 | - | Direct |
| Jun 23, 2026 | CADL Candel Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 32,000 | - | - | Direct |
| Jun 16, 2026 |  LQDA Liquidia Corp | Award(A) | 5,882 | - | $0 | Direct |
| Jun 4, 2026 | LQDA Liquidia Corp | Sale(S) | 11,513 | $63.13 | $726,816 | Indirect |
| Jun 4, 2026 | LQDA Liquidia Corp | Sale(S) | 88,487 | $64.28 | $5,687,944 | Indirect |
| Jun 4, 2026 | LQDA Liquidia Corp | Sale(S) | 19,125 | $62.62 | $1,197,608 | Indirect |
| Jun 4, 2026 | LQDA Liquidia Corp | Sale(S) | 68,265 | $63.83 | $4,357,355 | Indirect |
| Jun 4, 2026 | LQDA Liquidia Corp | Sale(S) | 12,610 | $64.42 | $812,336 | Indirect |
| Mar 31, 2026 | CADL Candel Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 4,618 | $4.11 | - | Direct |
| Feb 23, 2026 | CADL Candel Therapeutics, Inc. | Purchase(P) | 550,458 | $5.45 | $2,999,996 | Indirect |
| Feb 11, 2026 | LQDA Liquidia Corp | Other(J) | 55,116 | $42.63 | $2,349,595 | Indirect |
| Feb 11, 2026 | LQDA Liquidia Corp | Other(J) | 55,116 | $42.63 | $2,349,595 | Direct |
| Nov 25, 2025 |  VRCA Verrica Pharmaceuticals Inc. | Purchase(P) | 2,750,762 | $4.24 | $11,670,108 | Indirect |
| Nov 25, 2025 | VRCA Verrica Pharmaceuticals Inc. | Purchase(P) | 1,375,380 | $4.24 | $5,835,050 | Direct |
| Sep 2, 2025 | LQDA Liquidia Corp | Sale(S) | 74,230 | $29.14 | $2,163,062 | Indirect |
| Sep 2, 2025 | LQDA Liquidia Corp | Sale(S) | 254,038 | $28.67 | $7,283,269 | Indirect |
| Aug 29, 2025 | LQDA Liquidia Corp | Sale(S) | 188,232 | $27.62 | $5,198,968 | Indirect |
| Aug 28, 2025 | LQDA Liquidia Corp | Sale(S) | 154,337 | $27.94 | $4,312,176 | Indirect |
| Jun 25, 2025 | CADL Candel Therapeutics, Inc. | Award(A) | 1,070,663 | $4.67 | $4,999,996 | Indirect |
| Jun 17, 2025 | LQDA Liquidia Corp | Award(A) | 18,396 | - | - | Direct |
| Jun 17, 2025 | CADL Candel Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 14,240 | - | - | Direct |
| May 30, 2025 |  TSHA Taysha Gene Therapies, Inc. | Purchase(P) | 750,000 | $2.75 | $2,062,500 | Indirect |
| Dec 16, 2024 | CADL Candel Therapeutics, Inc. | Purchase(P) | 500,000 | $6.00 | $3,000,000 | Indirect |
| Dec 16, 2024 | CADL Candel Therapeutics, Inc. | Purchase(P) | 750,000 | $6.00 | $4,500,000 | Indirect |
1-25 of 33 transactions
About Manning Paul B
Manning Paul B (SEC CIK 0001494695) files insider reports with the SEC as Director of Candel Therapeutics, Inc. (CADL), Director of Liquidia Corp (LQDA) and Director of Verrica Pharmaceuticals Inc. (VRCA). Signal8 also holds filings tied to 1 other company.
Signal8 holds 18 ownership filings by Manning Paul B, all Form 4s, filed between Sep 16, 2024 and Oct 2, 2026. Those filings report 33 transactions, from Sep 12, 2024 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Manning Paul B's filings is in NEEDHAM, MA.
Recent filings by Manning Paul B
- Sep 30, 2026: Grant or award of CADL derivative securities (Form 4, code A).
- Jun 30, 2026: Grant or award of CADL derivative securities (Form 4, code A).
- Jun 23, 2026: Grant or award of CADL derivative securities (Form 4, code A).
- Jun 16, 2026: Grant or award of LQDA shares (Form 4, code A).
- Jun 4, 2026: Open-market sales of LQDA shares (5 lines, Form 4, code S).
Other insiders filing for Candel Therapeutics, Inc. (CADL)
- Loggia Nicoletta, Director
- PAPA JOSEPH C, Director
- Tak Paul Peter, Chief Executive Officer
- Zimmermann Martine, Director
- Tyagarajan Seshu, Chief Technology Officer
- Sims Mark E., Chief Commercial Officer